Shirin David

ReGen III Provides Corporate Progress Report

Retrieved on: 
수요일, 8월 30, 2023
U.S. Department of Energy, Office of Inspector General, Mexican Institute of Industrial Property, UMO, U.S. Department of Defense Strategy for Operating in Cyberspace, Regen, Finnish III Corps (Continuation War), Advanced Technology Vehicles Manufacturing Loan Program, Public, NBF, FSE, National bank, Recycling, IRA, LPO, Inflation, National Bank of Canada, RJF, Mexican Institute for Family and Population Research, Acquisition, Industrial property, Patent, Investment, Shirin David, Inflation Reduction Act of 2022, III, Air pollution, Copper, Cryptocurrency, Pharmaceutical industry, Q3

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - ReGen III Corp. (TSXV: GIII) (OTCQB: ISRJF) (FSE: PN4) ("ReGen III" or the "Company"), a leading clean technology company commercializing the ReGen™ patented process to recycle used motor oil ("UMO") into high-value Group III base oils, is pleased to provide the following corporate update.

Key Points: 
  • Physical samples of ReGen III's Group III base oils have been sent to a number of these entities for their in-house laboratory testing.
  • "In recent months, we have made significant progress," said Greg Clarkes, Chairman & CEO of ReGen III.
  • ReGen III is currently working through these comments with RJF's Public Finance/Debt Investment Banking team in advance of submitting the Company's formal application.
  • In addition to the LPO, ReGen III is exploring other incentives available to clean technology projects.

NEO Battery Materials Sends Optimized Silicon Anodes for Battery Performance Evaluation

Retrieved on: 
월요일, 8월 28, 2023
Lithium, Communication, EV, Toyota Battery Manufacturing North Carolina, NDA, Lithium iron phosphate, Lithium iron phosphate battery, Ink, LFP, Engineering, Ampere-hour, Sent, Shirin David, Silicon, OEM, NEO, Mobile phone

TORONTO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF)

Key Points: 
  • TORONTO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF)
    Optimized Batch of NEO’s Proprietary Silicon Anodes, NBMSiDE®, Sent for Battery Performance Evaluation & Characterization
    Undergoing 20+ Active Material Evaluations with Global Battery Cell/Material Manufacturers, EV Automakers
    6 NDAs Signed with Premium Automotive OEM, Battery Manufacturers, and Government & Increased R&D Capability for New Testing Initiatives
    NEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the latest optimized batch of NEO’s proprietary silicon anode materials, NBMSiDE®, has been sent to battery manufacturers and EV automakers for performance evaluation.
  • NEO Battery has continued sample delivery with multiple companies in the EV battery supply chain, undergoing over 20 active material evaluations to date.
  • Testing parties are undertaking various physical and electrochemical tests to characterize performance within their respective battery systems, and NEO actively provides optimized samples that fulfill specifications.
  • NEO will initiate silicon and graphite mixture anode testing to replicate commercial-level battery conditions.

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
월요일, 8월 14, 2023
Demodex, LIBRA, ESMO, Clinical trial, NDA, Oxford Handbook of Clinical Medicine, European Society of Cardiology, Oncology, CCA, NSCLC, European Society for Medical Oncology, AstraZeneca, Congress, Gene amplification, Hospital, Patient, EGFR, COE, BMS, Growth, Shirin David, European Society of Gynaecological Oncology, PD-1, ESC, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Stomach, HCM, FGFR2, NMPA, ORR, Food, Pharmaceutical industry, Cryptocurrency

SHANGHAI, China and PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023.
  • In April 2023, LianBio announced topline results from the Phase 3 EXPLORER-CN trial evaluating mavacamten in Chinese patients with oHCM.
  • LianBio expects to launch mavacamten in Singapore and Macau in the fourth quarter of 2023.
  • LianBio plans to file NDAs to support mavacamten approval in Taiwan and Thailand in the fourth quarter of 2023.

Diamond Sports Group Releases Cleansing Materials

Retrieved on: 
화요일, 8월 1, 2023
Entertainment, Communications, Sports, TV and Radio, General Sports, Media, Diamond, DSG, Shirin David, Creditor, Multimedia, Diamond Sports Group, Confidentiality, Cryptocurrency

Diamond Sports Group, LLC ("DSG," "Diamond," or the "Company"), today issued the following update along with unaudited financials.

Key Points: 
  • Diamond Sports Group, LLC ("DSG," "Diamond," or the "Company"), today issued the following update along with unaudited financials.
  • On or around June 29, 2023, Diamond entered into confidentiality agreements with certain holders of its funded indebtedness (the “Creditors”) in connection with the Creditors’ evaluation of a potential transaction involving Diamond and Diamond’s business plan.
  • Pursuant to the NDAs, Diamond agreed to publicly disclose certain information provided to the Creditors, including material non-public information, upon the occurrence of certain events set forth in the NDAs.
  • The Unaudited 2022 Financial Information is based solely on the information available to Diamond as of July 31, 2023.

ndaOK Unleashes Next-Level Efficiency in Legal Tech with GPT-4 Powered NDA Review

Retrieved on: 
화요일, 7월 25, 2023
Shirin David, NDA, AI, Private law, Medical device, Financial services, OpenAI

AUSTIN, Texas, July 25, 2023 /PRNewswire/ -- ndaOK, an innovator in AI-powered legal technology, today announces the launch of its next-generation non-disclosure agreement (NDA) review system. This advanced solution leverages OpenAI's GPT-4 large multimodal model, a first among legal technology companies, offering unprecedented performance and efficiency in reviewing NDAs.

Key Points: 
  • AUSTIN, Texas, July 25, 2023 /PRNewswire/ -- ndaOK , an innovator in AI-powered legal technology, today announces the launch of its next-generation non-disclosure agreement (NDA) review system.
  • This advanced solution leverages OpenAI's GPT-4 large multimodal model, a first among legal technology companies, offering unprecedented performance and efficiency in reviewing NDAs.
  • This unique capability makes ndaOK faster and easier to deploy than any other AI-based contract review solution.
  • ndaOK addresses the inefficiency of human NDA processing by using AI and automated workflows to review, revise, and execute NDAs.

Velia Therapeutics Announces Appointment of Veteran Drug Developer, John McHutchison, AO, MD as President and Chief Executive Officer

Retrieved on: 
수요일, 7월 19, 2023
Gilead Sciences, Therapy, AO, CSO, New Drug Application, Biotechnology, Foresite Capital, Proteome, Research, Doctor of Philosophy, Science, MD, Patient, SAN, Column, Shirin David, HBV, HCV, Management, Pharmaceutical industry

Dr. McHutchison is the former CEO and President at Assembly Biosciences, and a noted biotech industry leader with extensive executive experience.

Key Points: 
  • Dr. McHutchison is the former CEO and President at Assembly Biosciences, and a noted biotech industry leader with extensive executive experience.
  • He joins Shelly Meeusen, PhD, Chief Scientific Officer and Velia's scientific co-founders; Eric Olson, PhD, Alan Saghatelian, PhD, Richard Scheller, PhD and Jonathan Weissman, PhD.
  • a biotechnology company pioneering the therapeutic potential within the dark matter of the human proteome, backed by The Column Group and Foresite Capital, today announced the appointment of industry leader John McHutchison, AO, MD as President and Chief Executive Officer.
  • Millie Ray, PhD, Board Director at Velia, added, "We are extremely fortunate to have John join us at Velia.

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Retrieved on: 
월요일, 7월 3, 2023
Newton, Danforth, BS, Central nervous system, Therapy, Chairperson, Senior, KV3, BNC210, Comptroller, Biogen, Business operations, Audit, Neuroacanthocytosis, Connor, Drug, Boston, Educational Strategy for Developing Societies, BNO, ASX, MBA, Boston University, CNS, Development, Plasma protein binding, Strategic business unit, Newton-Wellesley Hospital, Patient, Vulnerability and Risk Committee, CPA, IND World's Fair Line, Hospital, Shirin David, KPMG, National Braille Association, Pharmaceutical industry, Management, Online shopping, Bionomics

Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.

Key Points: 
  • Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.
  • Mr. Fisher commented, “On behalf of the Board, I would like to express my excitement for Bionomics’ prospects and confidence in the team being assembled.
  • “Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products.
  • His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice.

modCounsel Launches mC IO, a Flat-Rate Contract Review Solution

Retrieved on: 
월요일, 6월 26, 2023
RFP, Sow, University, Thomson Reuters, IO, Research, Lawyer, Golden Joystick Awards, POS, CLOC, SAN, DPA Microphones, Entrepreneurship, Shirin David, Nursing, Video game

SAN FRANCISCO, June 26, 2023 /PRNewswire/ -- Today, modCounsel , a concierge legal services provider, officially launched mC IO , an end-to-end contract review solution designed to expedite the contract review process to help alleviate the workloads for busy legal professionals and departments.

Key Points: 
  • SAN FRANCISCO, June 26, 2023 /PRNewswire/ -- Today, modCounsel , a concierge legal services provider, officially launched mC IO , an end-to-end contract review solution designed to expedite the contract review process to help alleviate the workloads for busy legal professionals and departments.
  • However, without dedicated and experienced legal capacity to review, negotiate, and manage contracts, risk exposure amplifies as a company scales.
  • We created mC IO as the modern solution to help businesses get ahead of contracts and save busy legal teams from burnout."
  • We all know end-of-quarters are a race for attorneys and deal teams, but with modCounsel we can offer around-the-clock sales support.

Exro Announces Corporate Update Pertaining to Patent Applications, Operational Developments, and Upcoming Interest Payment

Retrieved on: 
금요일, 6월 23, 2023
DFM, Indian stock exchange, Partnership, EV, Interest, Toronto Stock Exchange, Electronics, Class, Torque, AB, NDA, Research, AC, FOC, IP, Certification, DC-DC, Link, Patent, UL (safety organization), Coil, Algorithm, Cell, Vehicle registration plates of Nepal, Deep diving, TSX, Shirin David, Austria, OEM, Modified due-date scheduling heuristic, Debenture, TSA, Due Date, Take a Look Inside, 3D printing, Rail transport, Security (finance), Electric motor, Mobile phone, Airline, Q3, European

Exro has filed two new U.S. provisional patent applications, presenting further powertrain uses for its technology, and strengthening Exro's intellectual property position.

Key Points: 
  • Exro has filed two new U.S. provisional patent applications, presenting further powertrain uses for its technology, and strengthening Exro's intellectual property position.
  • Exro has elected to issue common shares in satisfaction of interest payment due on June 30, 2023, under its C$15 Million convertible debentures.
  • While Exro will continue to use trade secrets to protect proprietary software and algorithms, it will look to bolster software-related patent filings in the coming quarters.
  • Exro anticipates receipt of the NDA-partners motor in Calgary by mid-Q3 2023 followed by pairing with Exro's Coil DriverTM.

New research highlights a significant and continued gap in achieving diversity in clinical trials of medical therapies

Retrieved on: 
수요일, 6월 21, 2023
Blas, Tufts Center for the Study of Drug Development, Takeda, Clinical trial, MBA, Research, PMP, Associate, Patient, Drug development, CSDD, Shirin David, FDA, DIA, Chief sustainability officer, Pharmaceutical industry, Management, Clario Tech

PHILADELPHIA, June 21, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

Key Points: 
  • Preliminary results are to be presented during the Drug Information Association (DIA) 2023 Annual Global Meeting .
  • Commenting on the research, Otis Johnson, Chief Diversity, Inclusion and Sustainability Officer, Clario, said, "lack of diversity in clinical trials means that the medicines, when approved, may not work for the underrepresented and could harm them.
  • It enables ease of trial access for a broader pool of participants with the potential to speed up trial enrollment.
  • It is also good for business, as the approved drugs can be confidently prescribed to a broader, more diverse patient population".